Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals (ICPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Intercept Pharmaceuticals 10 Hudson Yards 37th FL New York NY 10001 USA

P: 646-747-1000

Description:

Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.

Key Statistics

Overview:

Market Capitalization, $K 1,503,519
Shares Outstanding, K 32,943
Annual Sales, $ 252,000 K
Annual Net Income, $ -344,680 K
Last Quarter Sales, $ 72,650 K
Last Quarter Net Income, $ -92,980 K
60-Month Beta 1.78
% of Insider Shareholders 23.70%
% of Institutional Shareholders 76.22%
Float, K 25,136
% Float 76.30%

Growth:

1-Year Return -28.67%
3-Year Return -57.40%
5-Year Return -80.70%
5-Year Revenue Growth 14,382.76%
5-Year Earnings Growth 20.10%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.86 on 05/11/20
Next Earnings Date 08/05/20
Earnings Per Share ttm -10.72
EPS Growth vs. Prev Qtr 4.35%
EPS Growth vs. Prev Year 5.61%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

ICPT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -11.14
Price/Earnings to Growth N/A
Return-on-Equity % -430.51%
Return-on-Assets % -45.23%
Profit Margin % -136.78
Net Margin % N/A
Debt/Equity N/A
Price/Sales 6.10
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.05
Interest Coverage -7.38
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar